dea info plus gov patents on mmj

Dr.Pecker

Well-Known Member
I posted this in general growing but I dont think anyone cares.I have some important notes I think they may be useful to some people.
Please note exhibit a (pay close attention to the marihuana part).it states no medicinal value.
Drug Schedules
Drugs, substances, and certain chemicals used to make drugs are classified into five (5) distinct categories or schedules depending upon the drug’s acceptable medical use and the drug’s abuse or dependency potential. The abuse rate is a determinate factor in the scheduling of the drug; for example, Schedule I drugs are considered the most dangerous class of drugs with a high potential for abuse and potentially severe psychological and/or physical dependence. As the drug schedule changes-- Schedule II, Schedule III, etc., so does the abuse potential-- Schedule V drugs represents the least potential for abuse. A Listing of drugs and their schedule are located at Controlled Substance Act (CSA) Scheduling or CSA Scheduling by Alphabetical Order. These lists describes the basic or parent chemical and do not necessarily describe the salts, isomers and salts of isomers, esters, ethers and derivatives which may also be classified as controlled substances. These lists are intended as general references and are not comprehensive listings of all controlled substances.

Please note that a substance need not be listed as a controlled substance to be treated as a Schedule I substance for criminal prosecution. A controlled substance analogue is a substance which is intended for human consumption and is structurally or pharmacologically substantially similar to or is represented as being similar to a Schedule I or Schedule II substance and is not an approved medication in the United States. (See 21 U.S.C. §802(32)(A) for the definition of a controlled substance analogue and 21 U.S.C. §813 for the schedule.)
Schedule I

Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Schedule I drugs are the most dangerous drugs of all the drug schedules with potentially severe psychological or physical dependence. Some examples of Schedule I drugs are:

heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote

Schedule II

Schedule II drugs, substances, or chemicals are defined as drugs with a high potential for abuse, less abuse potential than Schedule I drugs, with use potentially leading to severe psychological or physical dependence. These drugs are also considered dangerous. Some examples of Schedule II drugs are:

cocaine, methamphetamine, methadone, hydromorphone (Dilaudid), meperidine (Demerol), oxycodone (OxyContin), fentanyl, Dexedrine, Adderall, and Ritalin

Schedule III

Schedule III drugs, substances, or chemicals are defined as drugs with a moderate to low potential for physical and psychological dependence. Schedule III drugs abuse potential is less than Schedule I and Schedule II drugs but more than Schedule IV. Some examples of Schedule III drugs are:

Combination products with less than 15 milligrams of hydrocodone per dosage unit (Vicodin), Products containing less than 90 milligrams of codeine per dosage unit (Tylenol with codeine), ketamine, anabolic steroids, testosterone

Schedule IV

Schedule IV drugs, substances, or chemicals are defined as drugs with a low potential for abuse and low risk of dependence. Some examples of Schedule IV drugs are:

Xanax, Soma, Darvon, Darvocet, Valium, Ativan, Talwin, Ambien

Schedule V

Schedule V drugs, substances, or chemicals are defined as drugs with lower potential for abuse than Schedule IV and consist of preparations containing limited quantities of certain narcotics. Schedule V drugs are generally used for antidiarrheal, antitussive, and analgesic purposes. Some examples of Schedule V drugs are:

cough preparations with less than 200 milligrams of codeine or per 100 milliliters (Robitussin AC), Lomotil, Motofen, Lyrica, Parepectolin now lets take a look at exhibit b a patent for a marihuana product patented for medicinal purposes
[US Patent & Trademark Office, Patent Full Text and Image Database]
[Home] [Boolean Search] [Manual Search] [Number Search] [Help]
[Bottom]
[View Shopping Cart] [Add to Shopping Cart]
[Image]
( 1 of 1 )
United States Patent 6,630,507
Hampson , et al. October 7, 2003
**Please see images for: ( Certificate of Correction ) **
Cannabinoids as antioxidants and neuroprotectants

Abstract
Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH.sub.3, and COCH.sub.3. ##STR1##

Inventors: Hampson; Aidan J. (Irvine, CA), Axelrod; Julius (Rockville, MD), Grimaldi; Maurizio (Bethesda, MD)
Assignee: The United States of America as represented by the Department of Health and Human Services (Washington, DC)
Family ID: 26767641
Appl. No.: 09/674,028
Filed: February 2, 2001
PCT Filed: April 21, 1999
PCT No.: PCT/US99/08769
PCT Pub. No.: WO99/53917
PCT Pub. Date: October 28, 1999
Current U.S. Class: 514/454
Current CPC Class: A61K 31/35 (20130101)
Current International Class: A61K 31/35 (20060101); A61K 031/35 ()
Field of Search: ;514/454
References Cited [Referenced By]
U.S. Patent Documents
2304669 December 1942 Adams
4876276 October 1989 Mechoulam et al.
5227537 July 1993 Stoss et al.
5284867 February 1994 Kloog et al.
5434295 July 1995 Mechoulam et al.
5462946 October 1995 Mitchell et al.
5512270 April 1996 Ghio et al.
5521215 May 1996 Mechoulam et al.
5538993 July 1996 Mechoulam et al.
5635530 June 1997 Mechoulam et al.
5696109 December 1997 Malfroy-Camine et al.
6410588 June 2002 Feldmann et al.
Foreign Patent Documents
427518 May 1991 EP
576357 Dec 1993 EP
656354 Jun 1995 EP
658546 Jun 1995 EP
WO9305031 Mar 1993 WO
WO9412667 Jun 1994 WO
WO9612485 May 1996 WO
WO9618600 Jun 1996 WO
WO9719063 May 1997 WO
99/53917 Oct 1999 So we have
So we can see it has no medicinal value but the us government has a patent on it for medicinal purposes this is clearly total bs. If any people are charged with a schedule 1 for marihuana possession then it should be challenged in court. IMO please feel free to comment.
 
Top